Navigation Links
Cephalon Announces Strong Third Quarter Financial Results
Date:11/8/2007

(1,881) 15,761

Other assets (28,552) (43,731)

Accounts payable and

accrued expenses 380,776 (45,820)

Other liabilities 49,465 (13,580)

Net cash provided by

operating activities 274,321 251,190

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of property and

equipment (70,887) (97,122)

Acquisition of intangible assets (99,152) (115,000)

Proceeds from sale of investment 12,291 -

Sales and (purchases) of

available-for-sale investments, net (43,186) 242,660

Net cash provided by (used for)

investing activities (200,934) 30,538

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from exercises of

common stock options 74,375 112,794

Windfall tax benefits from

stock-based compensation 9,934 21,912

Acquisition of treasury stock (128) (433)

Payments on and retirements of long-term

debt (2,902) (2,528)

Net cash provided by financing activities 81,279 131,745

EFFECT OF EXCHANGE RATE CHANGES ON

CASH AND CASH EQUIVALENTS 10,804 11,830

NET INCREASE IN CASH AND CASH EQUIVALENTS 165,470 425,303

CASH AND CASH EQUIVALENTS, BEGINNING

OF PERIOD 496,512 205,060

CASH AND CASH EQUIVALENTS, END OF PERIOD $661,982 $630,363

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of Proje
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources ... Brazil and Mexico ... uptake of several newly approved agents, the anticipated ... indication and the launch of emerging biologics will ... In particular, the emerging IL-5 inhibitors will introduce ...
(Date:8/21/2014)... VIEW, Calif. , Aug. 21, 2014 /PRNewswire/ ... properties and behaviors based on external stimuli such ... poised to have a disruptive effect in multiple ... revolutionize the business landscape by printing objects ranging ... aerospace and automotive sectors. Logo - ...
(Date:8/21/2014)... SoundConnect , a unified ... one of the nation’s Fastest Growing Private Companies ... 2nd consecutive year. Inc. magazine today ranked SoundConnect ... an exclusive ranking of the nation's fastest-growing private ... at the most important segment of the economy—America’s ...
(Date:8/20/2014)... often have it that American Indians largely were wiped ... influenza and tuberculosis brought to the New World by ... 20 million people lived in the Americas shortly before ... killed by European diseases., But new research led by ... Johannes Krause of the University of Tubingen in Germany ...
Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3
... Toronto Stock Exchange Symbol: MS , ... EDMONTON, AB , ... today announced its updated corporate strategy. The Company,s new strategy ... industry, whereby BioMS will directly invest in and advise companies ...
... , May 3 The Global Alliance for ... the 2010 BIO International Convention that they have entered into ... clinical use of drugs against tuberculosis (TB), including drug resistant ... are resistant to at least one of today,s standard first-line ...
... , WALTHAM, Mass. , May 3 Interleukin ... Lewis H. Bender will moderate and co-present a panel ... Development: How to Improve Efficacy and Commercial Success" at the BIO ... Chicago, IL.  The panel discussion will be held Wednesday, ...
Cached Biology Technology:BioMS updates corporate strategy and adds leading healthcare investment banker 2BioMS updates corporate strategy and adds leading healthcare investment banker 3TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 2TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 3TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 4Interleukin Genetics to Present at Upcoming Biotech Industry Meetings 2
(Date:8/21/2014)... team of researchers at Louisiana Tech University ... affordable, consumer-grade 3D printers and materials to ... antibacterial and chemotherapeutic compounds for targeted drug ... students and research faculty from Louisiana Tech,s ... to create filament extruders that can make ...
(Date:8/21/2014)... the pancreas digesting itself resulting in severe abdominal pain, ... around 20,000 patients are diagnosed with the disease resulting ... treatment is restricted to intravenous fluid and nutritional support. ... Life Sciences, who led the research, said "The major ... stones and excessive alcohol intake combined with a high ...
(Date:8/20/2014)... (HCI) at the University of Utah have identified and ... the unregulated enzyme driving the blood cancer chronic myeloid ... 6,000 new cases of CML will be diagnosed in ... inhibitors (TKIs), target BCR-ABL and are effective at controlling ... it in a way that allows patients to get ...
Breaking Biology News(10 mins):Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... an iron storage molecule in the cell can serve ... gene therapy may use a technique in which non-invasive ... molecule. The results of this research, conducted by Prof. ... were published in the research journal Neoplasia. , Neeman, ...
... at Washington University in St. Louis has shown that ... sexual organs, and actually choose them for mating. That ... called a gonopodium. These fish out-compete the larger-endowed males ... burst speed than the males with larger genitalia, who ...
... show that stem cell therapy can be used effectively to ... two months, stem cells harvested from another pig's bone marrow ... and repaired damaged heart muscle by 50 percent to 75 ... the 2004 Scientific Sessions of the American Heart Association, are ...
Cached Biology News:Novel live reporting system to track cells 2IMF Launches World’s First DNA Database for Myeloma Patients 2IMF Launches World’s First DNA Database for Myeloma Patients 3IMF Launches World’s First DNA Database for Myeloma Patients 4Stem cell therapy successfully treats heart attack in animals 2
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
...
... HDAC4 - ChIP Grade HDAC4 is ... histone deacetylases, which consists of 1084 amino ... similar to the deacetylase domain of yeast ... the nucleus and cytoplasm in a process ...
...
Biology Products: